Type of tumor	Immunohistochemical characteristics
Urothelial carcinoma	>90% CK7+, <60% CK20+, >80% p63+ and p40, 80% GATA3+, 80% EMA+, 50% CK5/6+, 50% Uroplakin 3+, 50% Vimentin+, 20% SATB2
Ovarian carcinoma (mucinous)	>90% CK7+, <60% CK20+, Gastric subtype: <10% Vimentin+ and ESR+, Endocervical subtype: 30-70% Vimentin+ and 30-90% ESR+
Small intestinal adenocarcinoma	60% CK7+, 60% CK20+, 50% CDX2+, 50% Glypican 3, 30% SATB2+, 40% OCT4+, MMR- in 90% for one of the proteins, >10% PSMA+, few cases Arginase 1+
Peritoneal pseudomyxoma	60-80% CK7+, >95% CK20+,>95% CDX2+
Gastric adenocarcinoma (subset)	<80% CK7+, <70% CK20+, <60% mCEA+, <60% CDX2+, 10% SATB2+ >90% CDH17+, 50% CDX2+
Lung adenocarcinoma with enteric differentiation	>95% CK7+, 60% CDX2+, 50% TTF1+, 40% CK20+, 30% Napsin A, <20% SATB2+, <10% Cadherin 17
Yolk sac tumor	<60% CK7+, <80% CK20+, 100% SALL4+, >90% Glypican 3+, <80% AFP+, >70% CDX2+, >40% PLAP+
Pancreas adenocarcinoma (ductal)	90% CK7+, 40% CK20+, 100% BAP1+, 80% EpCAM+, 70% CK17+, 70% CA125+, <50% CDH17+. <30% CDX2+, >40% DPC4/SMAD4
Cholangiocarcinoma (extrahepatic)	>90% CK7+, 10-20% CK20+, 30% CDX2, 70% mCEA+, >80% BAP1+, <5% SATB2+
Oesophageal adenocarcinoma	<90% CK7+, <50% CK20+, >80% CDH17+, 80% CDX2+